Procalcitonin concentration in the emergency department predicts 30-day mortality in COVID-19 better than the lymphocyte count, the neutrophil-tolymphocyte ratio, or the C-reactive protein level
OBJECTIVES: Although many demographic and clinical predictors of mortality have been studied in relation to COVID-19, little has been reported about the prognostic utility of inflammatory biomarkers.
MATERIAL AND METHODS: Retrospective cohort study. All patients with laboratory-confirmed COVID-19 treated in a hospital emergency department were included consecutively if baseline measurements of the following biomarkers were on record: lymphocyte counts, neutrophil-to-lymphocyte ratio NRL, and C-reactive protein (CRP) and procalcitonin (PCT) levels. We analyzed associations between the biomarkers and all-cause 30-day mortality using Cox regression models and dose-response curves.
RESULTS: We included 896 patients, 151 (17%) of whom died within 30 days. The median (interquartile range) age was 63 (51-78) years, and 494 (55%) were men. NLR, CRP and PCT levels at ED presentation were higher, while lymphocyte counts were lower, in patients who died compared to those who survived (P .001). The areas under the receiver operating characteristic curves revealed the PCT concentration (0.79; 95% CI, 0.75-0.83) to be a better predictor of 30-day mortality than the lymphocyte count (0.70; 95% CI, 0.65-0.74; P .001), the NLR (0.74; 95% CI, 0.69-0.78; P = .03), or the CRP level (0.72; 95% CI, 0.68-0.76; P .001). The proposed PCT concentration decision points for use in emergency department case management were 0.06 ng/L (negative) and 0.72 ng/L (positive). These cutoffs helped classify risk in 357 patients (40%). Multivariable analysis demonstrated that the PCT concentration had the strongest association with mortality.
CONCLUSION: PCT concentration in the emergency department predicts all-cause 30-day mortality in patients with COVID-19 better than other inflammatory biomarkers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias - 34(2022), 2 vom: 07. Apr., Seite 119-127 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Procalcitonina es superior a recuento linfocitario, índice neutrófilo/linfocito y proteína C reactiva para la predicción de mortalidad a 30 días de pacientes con COVID-19 en el servicio de urgencias |
|---|
| Anmerkungen: |
Date Completed 16.03.2022 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM338062777 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338062777 | ||
| 003 | DE-627 | ||
| 005 | 20231225235825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM338062777 | ||
| 035 | |a (NLM)35275462 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a López-Ayala, Pedro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Procalcitonin concentration in the emergency department predicts 30-day mortality in COVID-19 better than the lymphocyte count, the neutrophil-tolymphocyte ratio, or the C-reactive protein level |
| 246 | 3 | 3 | |a Procalcitonina es superior a recuento linfocitario, índice neutrófilo/linfocito y proteína C reactiva para la predicción de mortalidad a 30 días de pacientes con COVID-19 en el servicio de urgencias |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.03.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Although many demographic and clinical predictors of mortality have been studied in relation to COVID-19, little has been reported about the prognostic utility of inflammatory biomarkers | ||
| 520 | |a MATERIAL AND METHODS: Retrospective cohort study. All patients with laboratory-confirmed COVID-19 treated in a hospital emergency department were included consecutively if baseline measurements of the following biomarkers were on record: lymphocyte counts, neutrophil-to-lymphocyte ratio NRL, and C-reactive protein (CRP) and procalcitonin (PCT) levels. We analyzed associations between the biomarkers and all-cause 30-day mortality using Cox regression models and dose-response curves | ||
| 520 | |a RESULTS: We included 896 patients, 151 (17%) of whom died within 30 days. The median (interquartile range) age was 63 (51-78) years, and 494 (55%) were men. NLR, CRP and PCT levels at ED presentation were higher, while lymphocyte counts were lower, in patients who died compared to those who survived (P .001). The areas under the receiver operating characteristic curves revealed the PCT concentration (0.79; 95% CI, 0.75-0.83) to be a better predictor of 30-day mortality than the lymphocyte count (0.70; 95% CI, 0.65-0.74; P .001), the NLR (0.74; 95% CI, 0.69-0.78; P = .03), or the CRP level (0.72; 95% CI, 0.68-0.76; P .001). The proposed PCT concentration decision points for use in emergency department case management were 0.06 ng/L (negative) and 0.72 ng/L (positive). These cutoffs helped classify risk in 357 patients (40%). Multivariable analysis demonstrated that the PCT concentration had the strongest association with mortality | ||
| 520 | |a CONCLUSION: PCT concentration in the emergency department predicts all-cause 30-day mortality in patients with COVID-19 better than other inflammatory biomarkers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a C-reactive protein. | |
| 650 | 4 | |a COVID-19. | |
| 650 | 4 | |a Emergency department. | |
| 650 | 4 | |a Linfocitos. | |
| 650 | 4 | |a Lymphocytes. | |
| 650 | 4 | |a Neutrophil-to-lymphocyte ratio. | |
| 650 | 4 | |a Procalcitonin. | |
| 650 | 4 | |a Procalcitonina. | |
| 650 | 4 | |a Proteína C reactiva. | |
| 650 | 4 | |a Urgencias. | |
| 650 | 4 | |a Índice neutrófilos/linfocitos. | |
| 650 | 7 | |a Procalcitonin |2 NLM | |
| 650 | 7 | |a Calcitonin |2 NLM | |
| 650 | 7 | |a 9007-12-9 |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Alcaraz-Serna, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Valls Carbó, Adrián |e verfasserin |4 aut | |
| 700 | 1 | |a Cuadrado Cenzual, Mª Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Torrejón Martínez, María José |e verfasserin |4 aut | |
| 700 | 1 | |a López Picado, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez Valero, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Miranda, Juande D |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz Del Arco, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Cozar López, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Suárez-Cadenas, María Del Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Jerez Fernández, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Angós, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez Adrada, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Cardassay, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Del Toro, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Chaparro, David |e verfasserin |4 aut | |
| 700 | 1 | |a Montalvo Moraleda, María Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Espejo Paeres, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a García Briñón, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández Martín-Romo, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Pérez, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Novillo, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a González Armengol, Juan Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a González Del Castillo, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Christian E |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Sánchez, F Javier |e verfasserin |4 aut | |
| 700 | 0 | |a IdISSC-COVID-TASKFORCE and COVID-19_URG-HCSC Register investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias |d 1998 |g 34(2022), 2 vom: 07. Apr., Seite 119-127 |w (DE-627)NLM09743793X |x 2386-5857 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2022 |g number:2 |g day:07 |g month:04 |g pages:119-127 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2022 |e 2 |b 07 |c 04 |h 119-127 | ||